A Phase 1b Study Of Pembrolizumab In Combination With Trastuzumab-DM1 In Metastatic HER2-Positive Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 21 Feb 2017 Status changed from not yet recruiting to recruiting.
- 08 Feb 2017 Planned initiation date changed from 1 Feb 2017 to 1 Mar 2017.
- 03 Feb 2017 New trial record